GlassScriptPhysician profile
Christopher Jay Lamm
NPI 1346903432
$1,539.87
in general payments reported to CMS, 2019-2025
29 companies · $455 in 2025
The $455 reported for 2025 was more than what 75% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.67 · 2023: $506 · 2024: $517 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.72 |
| Education | $158.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.26 | 2024-2025 | |
| Beigene USA, INC. | $150.00 | 2024 | Brukinsa |
| Stemline Therapeutics INC. | $141.70 | 2023-2025 | Orserdu |
| Beone Medicines USA, INC. | $130.56 | 2025 | Brukinsa |
| Janssen Scientific Affairs, LLC | $120.78 | 2023 | Talvey, Tecvayli |
| Gilead Sciences, INC. | $88.18 | 2024 | Trodelvy |
| Sanofi-Aventis U.S. LLC | $84.99 | 2023 | |
| Genmab U.S., INC. | $80.75 | 2024-2025 | Epkinly, Tivdak |
| Janssen Biotech, INC. | $78.00 | 2023-2024 | Darzalex, Akeega, Balversa |
| Pfizer INC. | $55.25 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.90 | 2023-2025 | Ninlaro, Fruzaqla |
| Genentech USA, INC. | $40.72 | 2023 | Venclexta |
| Kyowa Kirin, INC. | $38.29 | 2023 | Poteligeo |
| Cumberland Pharmaceuticals, INC. | $33.79 | 2023-2024 | Sancuso |
| Jazz Pharmaceuticals INC. | $26.21 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24.81 | 2025 | |
| Syndax Pharmaceuticals, INC. | $22.46 | 2025 | |
| Merck Sharp & Dohme LLC | $21.92 | 2025 | Keytruda Qlex, Keytruda |
| Aveo Pharmaceuticals, INC. | $21.71 | 2024 | |
| Springworks Therapeutics, INC. | $20.25 | 2024 | Ogsiveo |
| Novo Nordisk INC | $19.59 | 2023 | |
| Amgen INC. | $17.83 | 2022 | |
| Incyte Corporation | $17.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.81 | 2025 | |
| Recordati_rare_diseases_inc. | $15.36 | 2025 | Sylvant |
| Astellas Pharma US INC | $15.16 | 2025 | Padcev |
| Glaxosmithkline, LLC. | $14.53 | 2024 | Ojjaara |
| Genzyme Corporation | $14.43 | 2022 | |
| Seagen INC. | $14.16 | 2023 | Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.